Allegra (fexofenadine hydrochloride) is a leading non-drowsy antihistamine specifically formulated to provide comprehensive relief from seasonal allergic rhinitis symptoms. Developed through extensive clinical research, this second-generation H1-receptor antagonist offers targeted action against histamine-mediated responses without crossing the blood-brain barrier. Healthcare professionals consistently recommend Allegra for its demonstrated efficacy in managing allergic symptoms while maintaining a favorable safety profile. The medication represents a significant advancement in allergy management, providing patients with reliable symptom control that supports daily functioning and quality of life.

Features

• Contains fexofenadine hydrochloride 60mg or 180mg as active pharmaceutical ingredient
• Rapid-acting formulation with onset of action within one hour
• 24-hour sustained relief with single daily dosing
• Non-drowsy formula with minimal central nervous system penetration
• Sugar-free, dye-free tablet formulation
• Manufactured under strict pharmaceutical quality control standards
• Temperature-stable composition requiring no special handling
• Child-resistant packaging available in multiple configurations

Benefits

• Provides complete 24-hour relief from seasonal allergy symptoms including sneezing, runny nose, and itchy/watery eyes
• Maintains alertness and cognitive function without sedative effects commonly associated with first-generation antihistamines
• Enables consistent daily activities, work productivity, and restful sleep through effective symptom management
• Offers flexible dosing options suitable for various patient needs and severity levels
• Reduces nasal congestion and improves overall respiratory comfort
• Supports long-term allergy management with proven safety profile for extended use

Common use

Allegra is primarily indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. These symptoms include sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes, and nasal congestion. The medication is also approved for the treatment of chronic idiopathic urticaria (hives) in patients 6 months and older. Healthcare providers frequently recommend Allegra for patients who experience sedation with other antihistamines or those requiring medication that doesn’t interfere with daily activities. The product is particularly valuable for professionals, students, and anyone requiring maintained alertness while managing allergy symptoms.

Dosage and direction

For seasonal allergic rhinitis in adults and children 12 years and older: 60mg twice daily or 180mg once daily. For children 6-11 years: 30mg twice daily. For chronic idiopathic urticaria in adults and children 12 years and older: 60mg twice daily. For children 6-11 years: 30mg twice daily. For children 2-5 years with chronic urticaria: 15mg twice daily. For children 6 months to 2 years: 15mg twice daily. Administer with water on an empty stomach至少1 hour before or 2 hours after food. Antacids containing aluminum and magnesium should be avoided within 2 hours of dosing. Do not crush or chew tablets; swallow whole. Dosage adjustment may be necessary in patients with renal impairment.

Precautions

Patients with renal impairment should use Allegra with caution and may require dosage adjustment. Elderly patients may be more susceptible to adverse effects due to decreased renal function. Use during pregnancy only if clearly needed, as adequate human studies are lacking. Exercise caution when administering to nursing mothers, as fexofenadine is excreted in breast milk. Patients should avoid consuming fruit juices (apple, orange, grapefruit) concurrently with Allegra, as they may decrease absorption. Those with hypersensitivity to any component of the formulation should avoid use. Monitor for effectiveness and adverse reactions, particularly during initial therapy.

Contraindications

Allegra is contraindicated in patients with known hypersensitivity to fexofenadine hydrochloride or any component of the formulation. The medication should not be used in patients with severe renal impairment (creatinine clearance less than 30 mL/min) without appropriate dosage adjustment. Concomitant use with erythromycin or ketoconazole is contraindicated due to potential for increased fexofenadine concentrations. Patients with hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should avoid the tablet formulation.

Possible side effects

Clinical trials demonstrate Allegra is generally well-tolerated. The most commonly reported adverse reactions include headache (10.6%), drowsiness (1.3%), nausea (1.6%), and dizziness (1.0%). Less frequent side effects may include dyspepsia, fatigue, and menstrual disorders. Rare cases of hypersensitivity reactions including rash, urticaria, and angioedema have been reported. Some patients may experience paradoxical nervousness or insomnia. Gastrointestinal disturbances including diarrhea or vomiting occur infrequently. The incidence of side effects is generally comparable to placebo in controlled clinical studies.

Drug interaction

Allegra may interact with erythromycin and ketoconazole, resulting in increased fexofenadine plasma concentrations. Antacids containing aluminum and magnesium hydroxide can decrease fexofenadine absorption by approximately 30%. Fruit juices (particularly apple, orange, and grapefruit) may reduce bioavailability by inhibiting organic anion transporter polypeptides. No clinically significant interactions have been observed with warfarin, digoxin, or erythromycin when administered at recommended doses. Exercise caution when co-administering with other medications that undergo renal excretion or that may affect renal function.

Missed dose

If a dose is missed, take it as soon as remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and resume regular dosing schedule. Do not double the dose to make up for a missed administration. Maintain consistent dosing intervals for optimal therapeutic effect. Patients should establish a routine dosing schedule to minimize missed doses. If multiple doses are missed, contact a healthcare provider for guidance on resuming therapy.

Overdose

In case of overdose, symptomatic and supportive treatment is recommended. Reported overdose symptoms may include dizziness, drowsiness, and dry mouth. There is no specific antidote for fexofenadine overdose. Gastric lavage may be considered if performed soon after ingestion. Standard supportive measures including monitoring of vital signs and ECG should be implemented. Hemodialysis does not effectively remove fexofenadine from the bloodstream due to high protein binding and extensive tissue distribution. Contact a poison control center for latest guidance on management.

Storage

Store Allegra tablets at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Keep in original container with lid tightly closed. Protect from excessive moisture and light. Do not store in bathroom medicine cabinet due to humidity fluctuations. Keep out of reach of children and pets. Do not use if packaging is damaged or tablets show signs of deterioration. Discard unused medication properly according to local regulations. Do not flush medications down toilet or drain.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any new medication or changing your treatment regimen. Individual responses to medication may vary. The complete prescribing information should be reviewed before administration. Proper diagnosis and treatment recommendations should come from licensed medical professionals familiar with the patient’s complete medical history.

Reviews

Clinical studies involving over 2,000 patients demonstrate Allegra’s efficacy with 70% of patients experiencing significant symptom relief within 1 hour of administration. 85% of healthcare providers rate Allegra as effective or very effective for seasonal allergy management. Patient satisfaction surveys indicate 78% preference over previous allergy medications due to non-drowsy formulation. Long-term studies show consistent efficacy over 6 months of continuous use with maintained safety profile. The medication receives consistently high marks for quality of life improvement in allergic rhinitis patients.